ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.332,49
0,94%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,0693
-0,15%
Bitcoin
61.403,15
-0,66%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Idorsia Ltd (0RQE)

  7. Idorsia Ltd (0RQE) News

0RQE

Idorsia (0RQE)

Idorsia Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0RQE
DatumZeitQuelleÜberschriftSymbolFirma
25/06/202417h45UK RegulatoryHigher cantonal composition authority approved the amendments to the terms of the 2024 convertible bondsLSE:0RQEIdorsia Ltd
21/06/202407h00UK RegulatoryIdorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ categoryLSE:0RQEIdorsia Ltd
13/06/202411h00UK RegulatoryIdorsia holds its Annual General Meeting of ShareholdersLSE:0RQEIdorsia Ltd
03/06/202407h00UK RegulatoryNew data with daridorexant to be presented at SLEEP 2024LSE:0RQEIdorsia Ltd
03/06/202407h00UK RegulatoryNew data with daridorexant to be presented at SLEEP 2024LSE:0RQEIdorsia Ltd
31/05/202407h00UK RegulatoryData from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024LSE:0RQEIdorsia Ltd
31/05/202407h00UK RegulatoryData from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024LSE:0RQEIdorsia Ltd
23/05/202407h00UK RegulatoryIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersLSE:0RQEIdorsia Ltd
23/05/202407h00UK RegulatoryIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersLSE:0RQEIdorsia Ltd
21/05/202407h00UK RegulatoryIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsLSE:0RQEIdorsia Ltd
21/05/202407h00UK RegulatoryIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsLSE:0RQEIdorsia Ltd
21/05/202406h50UK RegulatoryIdorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigorLSE:0RQEIdorsia Ltd
21/05/202406h50UK RegulatoryIdorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigorLSE:0RQEIdorsia Ltd
21/05/202406h40UK RegulatoryIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueLSE:0RQEIdorsia Ltd
21/05/202406h40UK RegulatoryIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueLSE:0RQEIdorsia Ltd
14/05/202417h45UK RegulatoryInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callLSE:0RQEIdorsia Ltd
14/05/202417h45UK RegulatoryInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callLSE:0RQEIdorsia Ltd
06/05/202418h35UK RegulatoryBondholders approve amended terms of the 2024 convertible bondsLSE:0RQEIdorsia Ltd
06/05/202418h35UK RegulatoryBondholders approve amended terms of the 2024 convertible bondsLSE:0RQEIdorsia Ltd
01/05/202418h00UK RegulatoryIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondLSE:0RQEIdorsia Ltd
01/05/202418h00UK RegulatoryIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondLSE:0RQEIdorsia Ltd
26/04/202407h00UK RegulatoryJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionLSE:0RQEIdorsia Ltd
26/04/202407h00UK RegulatoryJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionLSE:0RQEIdorsia Ltd
23/04/202407h00UK RegulatoryIdorsia publishes an invitation to a bondholder meetingLSE:0RQEIdorsia Ltd
23/04/202407h00UK RegulatoryIdorsia publishes an invitation to a bondholder meetingLSE:0RQEIdorsia Ltd
17/04/202407h00UK RegulatoryIdorsia publishes a Financial Status required for an upcoming bondholder meetingLSE:0RQEIdorsia Ltd
17/04/202407h00UK RegulatoryIdorsia publishes a Financial Status required for an upcoming bondholder meetingLSE:0RQEIdorsia Ltd
11/04/202407h00UK RegulatoryIdorsia takes steps to address short-term liquidity needsLSE:0RQEIdorsia Ltd
11/04/202407h00UK RegulatoryIdorsia takes steps to address short-term liquidity needsLSE:0RQEIdorsia Ltd
22/03/202407h00UK RegulatoryIdorsia thanks Guy Braunstein for his years of service as he retiresLSE:0RQEIdorsia Ltd
 Showing the most relevant articles for your search:LSE:0RQE

Kürzlich von Ihnen besucht

USOTC
NVPTF
Navitas Pete (PK)
LBNK
STNUSDT
Sting
USOTC
NGXXF
Ngex Minerals (QX)
USOTC
CIBY
CIBL (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten